Pfizer and Arvinas have landed on a buyer for newly approved breast cancer med Veppanu, selling off an exclusive global license to Rigel Pharmaceuticals for $85 million upfront and hundreds of ...

Amid apparent overtures from the Trump administration to curb public vaccine criticism ahead of the midterms this fall, the ...

Eli Lilly has paused an obesity awareness campaign in India in response to a regulatory notice about the rules on advertising ...

As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer. | As Bicara Therapeutics lines up ...

After positive momentum on the plan in late 2025, European Union lawmakers have taken a critical step toward implementing a ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...

Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. | Daiichi ...

Lilly has a long association with sports, having been a major part of the Tokyo Olympics and last month's hosting of the NCAA ...

President Donald Trump is set to fire FDA Commissioner Marty Makary, The Wall Street Journal reports, citing sources familiar ...

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion ...

With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a ...

Since the start of the decade, Eli Lilly has committed to spend more than $50 billion to bolster its United States ...